Glioblastoma and prolactinoma: a rare simultaneous occurrence

Abstract

The simultaneous development of two or more primary central nervous system (CNS) tumors of different cell types represents 0.9% of all diagnosed CNS tumors. To the best of our knowledge, the simultaneous occurrence of glioblastoma and pituitary adenomas has been reported four times in the English literature, with only two cases harboring prolactinoma and glioblastoma. We report a case of a 42-year-old male who was diagnosed with a sporadic co-occurrence of glioblastoma and a prolactin-secreting pituitary adenoma (prolactinoma). This case report discusses the clinical presentation, radiological/histopathological features, and outcome as well as reviewing the pertinent medical literature. Glioblastoma and a prolactin-secreting adenoma may be detected within the same patient. Further studies are required to delineate the tumorigenesis of the development and co-occurrence of multiple intracranial tumors.

Surgical treatment of pituitary neuroendocrine tumors with coexisting intracranial lesions: A case series and review of the literature

“…The coexistence of PitNET with other intracranial lesions is unusual, especially when patients with previous irradiation therapy for pituitary tumors have been excluded from the study. However, in the current medical literature, there are several case reports of PitNET associated with other intracranial lesions, such as craniopharyngiomas,[ 15 ] lymphomas,[ 32 ] gliomas,[ 4 ] aneurysms,[ 17 , 19 , 24 - 27 , 33 , 36 ] and meningiomas[ 1 , 5 , 11 , 13 , 22 , 30 , 35 , 41 , 42 ] among others. However, it should be noted that both aneurysms and meningiomas are the most consistently reported ones and even several pathophysiologic theories have been proposed to explain their association.…”

Concurrent Pituitary Adenoma and Intraventricular Glioblastoma Multiforme: A Case Report and Review of the Literature

“…However, this coexistence is rarely reported in the pertinent literature [9]. To our knowledge, only five cases of this coexistence have been previously reported [1,3,[9][10][11]. Among these, three cases were prolactinomas, and the remaining cases were nonfunctioning PA. All of GBMs from the five case reports located in the cerebral cortices which is the common location of GBM.…”

Functionalized Carbon Nano-Onions as a Smart Drug Delivery System for the Poorly Soluble Drug Carmustine for the Management of Glioblastoma

“…The reason is drug failure, poor pharmacokinetic properties, the appearance of resistance pathways, complex intratumoral heterogeneity, and improper design of clinical trials. Therefore, it is the need of the hour to evaluate drugs that have substantial efficacy at the preclinical stage itself so that failures at a later stage are subdued . A drug delivery system capable of specifically targeting the affected area while minimizing any negative impact on healthy tissues or organs within the human body would reduce drug dosage and uplift the drug’s safety profiles and good therapeutic indices.…”

“…Therefore, it is the need of the hour to evaluate drugs that have substantial efficacy at the preclinical stage itself so that failures at a later stage are subdued. 3 A drug delivery system capable of specifically targeting 4 the affected area while minimizing any negative impact on healthy tissues or organs within the human body would reduce drug dosage and uplift the drug's safety profiles and good therapeutic indices. The potential of carbon nanocarriers or carbon nanoparticles (CNPs), such as fullerene, carbon nanotubes, carbon nanohorns, carbon dots, and carbon nano-onions (CNOs), has been explored widely in recent days.…”